Swedish Orphan gains Korean partner for two products
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum (Sobi) has reached a deal for the distribution of two products for rare disorders in South Korea, linking up with the local firm BL&H for Orfadin (nitisone) and Kepivance (recombinant palifermin).